The Notch signaling pathway as a mediator of tumor survival

Kathleen M. Capaccione, Sharon Pine

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

The Notch signaling pathway is evolutionarily conserved and responsible for cell fate determination in the developing embryo and mature tissue. At the molecular level, ligand binding activates Notch signaling by liberating the Notch intracellular domain, which then translocates into the nucleus and activates gene transcription. Despite the elegant simplicity of this pathway, which lacks secondary messengers or a signaling cascade, Notch regulates gene expression in a highly context- and cell-type-dependent manner. Notch signaling is frequently dysregulated, most commonly by overactivation, across many cancers and confers a survival advantage on tumors, leading to poorer outcomes for patients. Recent studies demonstrate how Notch signaling increases tumor cell proliferation and provide evidence that active Notch signaling maintains the cancer stem-cell pool, induces epithelial- mesenchymal transition and promotes chemoresistance. These studies imply that pharmacological inhibition of Notch signaling may refine control of cancer therapy and improve patient survival. Gamma secretase inhibitors (GSIs) are drugs that inhibit Notch signaling and may be successful in controlling cancer cell growth in conjunction with standard chemotherapy, but substantial side effects have hampered their widespread use. Recent efforts have been aimed at the development of antibodies against specific Notch receptors and ligands with the hope of limiting side effects while providing the same therapeutic benefit as GSIs. Together, studies characterizing Notch signaling and modulation have offered hope that refined methods targeting Notch may become powerful tools in anticancer therapeutics.

Original languageEnglish (US)
Pages (from-to)1420-1430
Number of pages11
JournalCarcinogenesis
Volume34
Issue number7
DOIs
StatePublished - Jul 1 2013

Fingerprint

Survival
Amyloid Precursor Protein Secretases
Neoplasms
Notch Receptors
Ligands
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Therapeutics
Embryonic Structures
Cell Proliferation
Pharmacology
Gene Expression
Drug Therapy
Antibodies
Growth
Pharmaceutical Preparations
Genes

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

Capaccione, Kathleen M. ; Pine, Sharon. / The Notch signaling pathway as a mediator of tumor survival. In: Carcinogenesis. 2013 ; Vol. 34, No. 7. pp. 1420-1430.
@article{b76538c3af424c15b50a2464720737d3,
title = "The Notch signaling pathway as a mediator of tumor survival",
abstract = "The Notch signaling pathway is evolutionarily conserved and responsible for cell fate determination in the developing embryo and mature tissue. At the molecular level, ligand binding activates Notch signaling by liberating the Notch intracellular domain, which then translocates into the nucleus and activates gene transcription. Despite the elegant simplicity of this pathway, which lacks secondary messengers or a signaling cascade, Notch regulates gene expression in a highly context- and cell-type-dependent manner. Notch signaling is frequently dysregulated, most commonly by overactivation, across many cancers and confers a survival advantage on tumors, leading to poorer outcomes for patients. Recent studies demonstrate how Notch signaling increases tumor cell proliferation and provide evidence that active Notch signaling maintains the cancer stem-cell pool, induces epithelial- mesenchymal transition and promotes chemoresistance. These studies imply that pharmacological inhibition of Notch signaling may refine control of cancer therapy and improve patient survival. Gamma secretase inhibitors (GSIs) are drugs that inhibit Notch signaling and may be successful in controlling cancer cell growth in conjunction with standard chemotherapy, but substantial side effects have hampered their widespread use. Recent efforts have been aimed at the development of antibodies against specific Notch receptors and ligands with the hope of limiting side effects while providing the same therapeutic benefit as GSIs. Together, studies characterizing Notch signaling and modulation have offered hope that refined methods targeting Notch may become powerful tools in anticancer therapeutics.",
author = "Capaccione, {Kathleen M.} and Sharon Pine",
year = "2013",
month = "7",
day = "1",
doi = "10.1093/carcin/bgt127",
language = "English (US)",
volume = "34",
pages = "1420--1430",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "7",

}

The Notch signaling pathway as a mediator of tumor survival. / Capaccione, Kathleen M.; Pine, Sharon.

In: Carcinogenesis, Vol. 34, No. 7, 01.07.2013, p. 1420-1430.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The Notch signaling pathway as a mediator of tumor survival

AU - Capaccione, Kathleen M.

AU - Pine, Sharon

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The Notch signaling pathway is evolutionarily conserved and responsible for cell fate determination in the developing embryo and mature tissue. At the molecular level, ligand binding activates Notch signaling by liberating the Notch intracellular domain, which then translocates into the nucleus and activates gene transcription. Despite the elegant simplicity of this pathway, which lacks secondary messengers or a signaling cascade, Notch regulates gene expression in a highly context- and cell-type-dependent manner. Notch signaling is frequently dysregulated, most commonly by overactivation, across many cancers and confers a survival advantage on tumors, leading to poorer outcomes for patients. Recent studies demonstrate how Notch signaling increases tumor cell proliferation and provide evidence that active Notch signaling maintains the cancer stem-cell pool, induces epithelial- mesenchymal transition and promotes chemoresistance. These studies imply that pharmacological inhibition of Notch signaling may refine control of cancer therapy and improve patient survival. Gamma secretase inhibitors (GSIs) are drugs that inhibit Notch signaling and may be successful in controlling cancer cell growth in conjunction with standard chemotherapy, but substantial side effects have hampered their widespread use. Recent efforts have been aimed at the development of antibodies against specific Notch receptors and ligands with the hope of limiting side effects while providing the same therapeutic benefit as GSIs. Together, studies characterizing Notch signaling and modulation have offered hope that refined methods targeting Notch may become powerful tools in anticancer therapeutics.

AB - The Notch signaling pathway is evolutionarily conserved and responsible for cell fate determination in the developing embryo and mature tissue. At the molecular level, ligand binding activates Notch signaling by liberating the Notch intracellular domain, which then translocates into the nucleus and activates gene transcription. Despite the elegant simplicity of this pathway, which lacks secondary messengers or a signaling cascade, Notch regulates gene expression in a highly context- and cell-type-dependent manner. Notch signaling is frequently dysregulated, most commonly by overactivation, across many cancers and confers a survival advantage on tumors, leading to poorer outcomes for patients. Recent studies demonstrate how Notch signaling increases tumor cell proliferation and provide evidence that active Notch signaling maintains the cancer stem-cell pool, induces epithelial- mesenchymal transition and promotes chemoresistance. These studies imply that pharmacological inhibition of Notch signaling may refine control of cancer therapy and improve patient survival. Gamma secretase inhibitors (GSIs) are drugs that inhibit Notch signaling and may be successful in controlling cancer cell growth in conjunction with standard chemotherapy, but substantial side effects have hampered their widespread use. Recent efforts have been aimed at the development of antibodies against specific Notch receptors and ligands with the hope of limiting side effects while providing the same therapeutic benefit as GSIs. Together, studies characterizing Notch signaling and modulation have offered hope that refined methods targeting Notch may become powerful tools in anticancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84880306937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880306937&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgt127

DO - 10.1093/carcin/bgt127

M3 - Article

VL - 34

SP - 1420

EP - 1430

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 7

ER -